---
layout: default
title: Sitagliptin
parent: Model Prediction Only (L5)
nav_order: 634
evidence_level: L5
indication_count: 10
---

# Sitagliptin
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sitagliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia

## One-Sentence Summary

Sitagliptin is a DPP-4 inhibitor most widely known for the treatment of type 2 diabetes mellitus. The TxGNN model predicts it may be effective for **Opsismodysplasia**, a rare congenital skeletal dysplasia, but this prediction is currently supported by **zero clinical trials** and **zero publications** — and the model's own rationale notes no known mechanistic overlap between the DPP-4/incretin pathway and the disease's underlying biology.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Type 2 Diabetes Mellitus *(well-established pharmacological use; not confirmed via a formal regulatory record in this evidence pack — see Data Gap note below)* |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 98.87% |
| Evidence Level | L5 (model prediction only) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the evidence pack (flagged as a High-severity data gap). Based on generally known pharmacology, sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by prolonging the activity of endogenous incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion — its efficacy in type 2 diabetes mellitus is well established.

Opsismodysplasia, however, is a rare autosomal recessive skeletal dysplasia caused by mutations in *INPPL1*, which disrupts intracellular signalling involved in bone growth. According to the evidence pack's own repurposing rationale, there is **no known intersection** between this pathway and the DPP-4/incretin axis. The high TxGNN score therefore appears to reflect a knowledge-graph embedding similarity (e.g. shared metabolic or growth-related network neighbours) rather than a biologically grounded mechanism.

This pattern is not isolated to the top-ranked candidate: across all 10 predicted indications in this evidence pack, none show a plausible mechanistic link to sitagliptin's known pharmacology, and even the candidate with the most literature support (pancreatic agenesis, rank 6, evidence level L4) is explicitly noted as mechanistically implausible — DPP-4 inhibition requires functional islet cells, which are absent by definition in that condition. As such, this evidence pack should be read as an early-stage hypothesis-generation output rather than a clinically actionable signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Australia Market Information

Sitagliptin is **not currently marketed** in Australia under this evidence pack's regulatory data source (0 ARTG entries recorded).

---

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Note: this evidence pack flags TFDA/label warning and contraindication data as a **Blocking** data gap (DG001) — meaning a formal S1 safety pre-screen cannot currently be completed for this candidate.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication (opsismodysplasia) has no clinical trials, no published literature, and no mechanistic rationale beyond a knowledge-graph similarity score. Combined with the drug not being marketed in Australia and a Blocking-severity gap in safety/label data, there is currently no basis to advance this candidate.

**To proceed, the following is needed:**
- TGA-approved Product Information (warnings, contraindications, drug interactions)
- Confirmed mechanism of action and original indication from a primary regulatory source
- Independent mechanistic or preclinical rationale connecting DPP-4 inhibition to opsismodysplasia pathophysiology (currently absent)
- If pursuing this drug for repurposing more broadly, reassessment against candidates with stronger biological plausibility, since all 10 predictions in this pack are flagged Hold at evidence level L4–L5
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

